agalsidase beta: clinical use

Prescribing considerations

• Treatment should be supervised by a clinician experienced in Fabry disease or another inherited metabolic disorder.
• Consider home infusion only after satisfactory tolerance, individual assessment and appropriate training.
• Infusion-associated reactions may require interruption or slowing of administration and appropriate symptomatic treatment.
• Therapeutic renal effects may be limited once advanced renal disease is established.
• Record the product name and batch number for biological traceability.

Contraindications and cautions

• Life-threatening hypersensitivity or anaphylaxis to agalsidase beta or an excipient.

Monitoring

• Observe for infusion-associated and immediate hypersensitivity reactions.
• Monitor anti-agalsidase beta antibody status regularly, particularly when infusion reactions occur.
• Review ongoing renal, cardiac, neurological and other Fabry disease manifestations through the specialist service.
• Assess infusion tolerance before considering or continuing home administration.

Clinical pharmacology

Agalsidase beta is recombinant human alpha-galactosidase A produced in mammalian cells. Following intravenous administration, it is taken into lysosomes through carbohydrate-recognising receptors and is subsequently degraded through normal protein pathways; renal elimination is a minor clearance route.

Formulation and product differences

• The selected product is a refrigerated, single-use powder for concentrate that requires aseptic reconstitution and further dilution before intravenous infusion.
• The reconstituted solution should be promptly diluted, must not be mixed with other medicines in the same infusion and should be inspected for particles or discolouration.

Solution for infusion

Route: Intravenous

Strengths: 5 mg, 35 mg